Dexcom Inc
NASDAQ:DXCM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
64
140.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dexcom Inc
Wall Street
Price Targets
DXCM Price Targets Summary
Dexcom Inc
According to Wall Street analysts, the average 1-year price target for
DXCM
is 100.36 USD
with a low forecast of 75.75 USD and a high forecast of 152.25 USD.
DXCM Last Price Targets
Dexcom Inc
The latest public price target was made on Oct 8, 2024 by
Shagun Singh
from
RBC Capital
,
who expects
DXCM
stock to
rise by 50%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Shagun Singh
RBC Capital
|
120
USD
Upside 50% |
2 months ago
Oct 8, 2024
|
DexCom price target lowered to $120 from $130 at RBC Capital
TheFly
|
Mathew Blackman
Stifel Nicolaus
|
100
USD
Upside 25% |
4 months ago
Aug 22, 2024
|
DexCom price target raised to $100 from $90 at Stifel
TheFly
|
|
Shagun Singh
RBC Capital
|
130
USD
Upside 62% |
4 months ago
Aug 16, 2024
|
DexCom price target lowered to $130 from $145 at RBC Capital
TheFly
|
Matt Miksic
Barclays
|
113
USD
Upside 41% |
4 months ago
Jul 29, 2024
|
DexCom price target lowered to $113 from $138 at Barclays
TheFly
|
|
Shagun Singh
RBC Capital
|
145
USD
Upside 81% |
4 months ago
Jul 26, 2024
|
DexCom (DXCM) PT Lowered to $145 at RBC Capital
StreetInsider
|
Steven Lichtman
Oppenheimer
|
115
USD
Upside 43% |
4 months ago
Jul 26, 2024
|
DexCom price target lowered to $115 from $150 at Oppenheimer
TheFly
|
Matt O\'Brien
Piper Sandler
|
90
USD
Upside 12% |
4 months ago
Jul 26, 2024
|
DexCom (DXCM) PT Lowered to $90 at Piper Sandler
StreetInsider
|
William Plovanic
Canaccord Genuity
|
89
USD
Upside 11% |
4 months ago
Jul 26, 2024
|
DexCom price target lowered to $89 from $145 at Canaccord
TheFly
|
|
Mathew Blackman
Stifel Nicolaus
|
132
USD
Upside 65% |
5 months ago
Jul 12, 2024
|
DexCom price target lowered to $132 from $145 at Stifel
TheFly
|
|
Steven Lichtman
Oppenheimer
|
150
USD
Upside 87% |
6 months ago
Jun 3, 2024
|
Oppenheimer Reiterates Outperform Rating on DexCom (DXCM)
StreetInsider
|
|
Issie Kirby
Redburn Partners
|
130
USD
Upside 62% |
6 months ago
May 30, 2024
|
DexCom initiated with a Neutral at Redburn Atlantic
TheFly
|
|
Shagun Singh
RBC Capital
|
165
USD
Upside 106% |
9 months ago
Mar 12, 2024
|
DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says
Benzinga
|
|
Steven Lichtman
Oppenheimer
|
122
USD
Upside 52% |
1 year ago
Oct 27, 2023
|
MedTech Giant DexCom Spotlight Is On G7 US Launch, Analyst Forecasts 22% Revenue Gain In 2024
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is DXCM's stock price target?
Price Target
100.36
USD
According to Wall Street analysts, the average 1-year price target for
DXCM
is 100.36 USD
with a low forecast of 75.75 USD and a high forecast of 152.25 USD.
What is Dexcom Inc's Revenue forecast?
Projected CAGR
15%
For the last 8 years the
compound annual growth rate for
Dexcom Inc's revenue is
32%.
The projected
CAGR
for the next 4 years is
15%.
What is Dexcom Inc's Operating Income forecast?
Projected CAGR
25%
The
compound annual growth rate
of Dexcom Inc's operating income for the next 4 years is
25%.
What is Dexcom Inc's Net Income forecast?
Projected CAGR
21%
The
compound annual growth rate
of Dexcom Inc's net income for the next 4 years is
21%.
You don't have any saved screeners yet
